Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 13, 2018 - Issue
Submit an article Journal homepage
63
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD

Yasushi Fukushima1 Department of Internal Medicine, Fukuwa Clinic, Tokyo, Japan
,
Yuji Nakatani2 Department of Internal Medicine, Nakatani Hospital, Hyogo, Japan
,
Yumiko Ide3 Department of Internal Medicine, Tokyo Center Clinic, Tokyo, Japan
,
Hisakuni Sekino4 Department of Internal Medicine, Sekino Hospital, Tokyo, Japan
,
Earl St Rose5 Pearl – a member of the AstraZeneca Group, Morristown, NJ, USA
,
Shahid Siddiqui6 AstraZeneca, Gaithersburg, MD, USA
,
Andrea Maes5 Pearl – a member of the AstraZeneca Group, Morristown, NJ, USA
&
Colin Reisner5 Pearl – a member of the AstraZeneca Group, Morristown, NJ, USA;6 AstraZeneca, Gaithersburg, MD, USACorrespondence[email protected]
 show all
Pages 1187-1194 | Published online: 13 Apr 2018

References

  • BurneyPGPatelJNewsonRMinelliCNaghaviMGlobal and regional trends in COPD mortality, 1990–2010Eur Respir J20154551239124725837037
  • LozanoRNaghaviMForemanKGlobal and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet201238098592095212823245604
  • GBD 2015 Chronic Respiratory Disease CollaboratorsGlobal, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015Lancet Respir Med20175969170628822787
  • Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management and Prevention of COPD [updated 2018] Available from: http://www.goldcopd.orgAccessed February 22, 2018
  • GBD 2016 Causes of Death CollaboratorsGlobal, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016Lancet2017390101001151121028919116
  • LandisSHMuellerovaHManninoDMContinuing to confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013Int J Chron Obstruct Pulmon Dis2014959761124944511
  • FukuchiYNishimuraMIchinoseMCOPD in Japan: the Nippon COPD Epidemiology studyRespirology20049445846515612956
  • NishimuraSZaherCCost impact of COPD in Japan: opportunities and challenges?Respirology20049446647315612957
  • Japanese Respiratory SocietyJapanese Respiratory Society Guidelines for the Diagnosis and Treatment of COPD [updated 2009] Available from: http://www.jrs.or.jp/Accessed February 22, 2018
  • CazzolaMPageCPCalzettaLMateraMGPharmacology and therapeutics of bronchodilatorsPharmacol Rev201264345050422611179
  • BoniniMUsmaniOSThe importance of inhaler devices in the treatment of COPDCOPD Res Pract201519
  • BraidoFChrystynHBaiardiniIRespiratory Effectiveness Group“Trying, but failing” – The role of inhaler technique and mode of delivery in respiratory medication adherenceJ Allergy Clin Immunol Pract20164582383227587316
  • VehringRLechuga-BallesterosDJoshiVNogaBDwivediSKCosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalersLangmuir20122842150151502322985189
  • AstraZeneca Pharmaceuticals LPBevespi Aerosphere™ Prescribing Information [updated 2017] Available from: http://www.azpicentral.com/bevespi/bevespi_pi.pdfAccessed February 5, 2018
  • FabbriLMKerwinEMSpangenthalSDose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPDRespir Res201617110927586537
  • TashkinDPMartinezFJRodriguez-RoisinRA multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPDRespir Med2016120162427817811
  • ReisnerCFabbriLMKerwinEMA randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary diseaseRespir Res2017181828061907
  • WilliamsEJExperimental designs balanced for the estimation of residual effects of treatmentsAust J Sci Res B194922149168
  • MillerMRHankinsonJBrusascoVATS/ERS Task ForceStandardisation of spirometryEur Respir J200526231933816055882
  • JonesPWBeehKMChapmanKRDecramerMMahlerDAWedzichaJAMinimal clinically important differences in pharmacological trialsAm J Respir Crit Care Med2014189325025524383418
  • ReisnerCOrevilloCFernandezCPooled analyses of five phase 2b studies support dose selection of glycopyrrolate-formoterol fumarate (GFF) MDI (PT003) 18/9.6 μg for phase III developmentEur Respir J201342Suppl 57P4153
  • MartinezFJRabeKFFergusonGTEfficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPDChest2017151234035727916620
  • BattistiWPWagerEBaltzerLInternational Society for Medical Publication ProfessionalsGood publication practice for communicating company-sponsored medical research: GPP3Ann Intern Med2015163646146426259067

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.